Lysosomal cysteine proteases: facts and opportunities

EMBO Journal, 2001

749 citations recorded by the source corpus.

Subfields: Cancer Research, Cell Biology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/bce54e4e8c919f0ce5972b9cbe1b359f270a4c5c

Citations in the corpus

• Cysteine cathepsins: From structure, function and regulation to new frontiers (2011, neutral): “degrade intracellular and extracellular proteins [17,21].”
• Distinct Patterns of IFITM-Mediated Restriction of Filoviruses, SARS Coronavirus, and Influenza A Virus (2011, positive): “The entry processes of MARV and EBOV require activation by one or more cathepsins, whose activity is localized to lysosomes [10,12,13,17].”
• Extracellular matrix structure. (2016, neutral): “a reducing and slightly acidic environment are required [306, 307].”
• Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. (2004, neutral): “CANCER CELL : MAY 2004 · VOL. 5 · COPYRIGHT 2004 CELL PRESS 443 (Turk et al., 2001) and protein processing in other intracellular progressive increase in overall levels of cathepsin activity during organelles (e.g., hormone secretory granules [Yasothornsrikul RIP1-Tag2 tumorigenesis (Figure 1C).”
• Mediators of Chronic Obstructive Pulmonary Disease (2004, neutral): “Lysosomal cysteine proteases (cathepsins) may also be involved in COPD (Chapman et al., 1997; Turk et al., 2001).”
• Lysosomal membrane permeabilization in cell death (2008, neutral): “Cystatins are not very selective and inhibit endopeptidases in the picomolar range and exopeptidases in the nanomolar range (Turk et al., 2001).”
• Apoptosis and melanoma chemoresistance (2003, positive): “Mounting evidence indicates that in addition to apoptosis, nonapoptotic mechanisms may also contribute to the outcome of cancer therapy (Johnson, 2000; Leist and Jaattela, 2001; Turk et al., 2001).”